An increasing number of a diverse class of small molecule inhibitors (SMIs) of Bcl-2 can be specifically used for their therapeutic potential by inducing synthetic lethality in tumor cells with other oncogenic driver mutations. This evidence concerns the gene BCL2 and neoplasm.